Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
CSA Z1220-17: Ensuring Safe and Effective Pharmacy-Based Immunization Services in Canada
A Comprehensive Guide to the National Standard of Canada for Immunization Services Provided by Pharmacy Professionals
1. Scope and Purpose of CSA Z1220-17
CSA Z1220-17, titled Immunization Services for Pharmacy Professionals, is a National Standard of Canada developed by the Canadian Standards Association (CSA Group). Its purpose is to establish uniform, evidence-based requirements for the delivery of safe and effective immunization services within community pharmacies. The standard applies to all pharmacy professionals—including pharmacists and pharmacy technicians—who are authorized to assess, recommend, and administer vaccines in a pharmacy setting.
Scope: The standard encompasses the complete cycle of immunization service delivery, from pre-screening and vaccine storage through administration, post-vaccination monitoring, and documentation. It covers all vaccines that may be provided in a pharmacy under federal and provincial regulations. Key areas addressed include:
- Professional competency and training requirements
- Vaccine procurement, storage, handling, and cold chain integrity
- Patient eligibility assessment and informed consent
- Administration techniques and infection prevention and control (IPC)
- Adverse event management and reporting
- Privacy, confidentiality, and record-keeping
- Quality assurance and continuous improvement
The standard was last confirmed in 2017 and remains a foundational reference for pharmacy regulatory authorities, public health agencies, and pharmacy operators seeking to implement or benchmark immunization services.
2. Technical Requirements for Immunization Service Delivery
CSA Z1220-17 prescribes a comprehensive set of technical requirements organized around the patient care pathway. The following subsections outline the most critical elements.
2.1 Eligibility and Pre-Screening
Before administering a vaccine, the pharmacy professional must perform a tailored screening to verify that the patient meets age, health status, and vaccination history criteria. The standard mandates the use of a standardized screening tool, such as the provincial or National Advisory Committee on Immunization (NACI) questionnaire, to identify contraindications and precautions (e.g., allergies, immunosuppression, previous reactions).
2.2 Training and Competency
Pharmacy professionals must complete a recognized immunization training program that covers vaccine science, injection technique, anaphylaxis management, and CPR. The standard requires initial certification plus ongoing recertification (typically every 2–3 years) to maintain competency. Simulated practice and supervised clinical experience are recommended components.
2.3 Vaccine Storage and Handling
Vaccines must be stored in dedicated, temperature-controlled refrigeration units that maintain a consistent temperature range of +2°C to +8°C. The standard specifies requirements for:
- Continuous temperature monitoring using calibrated data loggers
- Daily temperature logs and corrective action plans for excursions
- Vaccine segregation from non-pharmaceutical items
- Cold chain management during transport
Tip: CSA Z1220-17 recommends the use of digital continuous monitoring systems with alarms. Data loggers should be checked and calibrated at least annually. Always store vaccines in the middle of the unit—never in the door or near the cooling vents—to avoid temperature variability.
| Vaccine Type | Storage Temperature | Light Sensitivity | Cold Chain Criticality |
|---|---|---|---|
| Influenza (inactivated) | +2°C to +8°C | Protect from light | High |
| COVID-19 mRNA (e.g., Comirnaty) | −80°C or −20°C (ultra-cold) or +2°C to +8°C (diluted) | Protect from light | Extreme |
| Pneumococcal (PPSV23, PCV13) | +2°C to +8°C | Protect from light | High |
| Tdap | +2°C to +8°C | Not required | Moderate |
| Herpes Zoster | +2°C to +8°C | Protect from light | High |
2.4 Administration and Technique
The standard defines the aseptic injection procedure, including proper hand hygiene, skin preparation, needle selection, shot location (usually deltoid muscle), and dose verification. Use of separate vaccination stations and adherence to the “five rights” (right patient, right vaccine, right dose, right route, right time) are mandatory.
2.5 Post-Administration Monitoring and Adverse Event Management
Patients must be observed for at least 15 minutes (30 for those with a history of allergy) for signs of immediate allergic reaction. The pharmacy must have a written emergency protocol and anaphylaxis kit (epinephrine auto-injectors) available. All adverse events following immunization (AEFI) must be documented and reported to the local public health unit according to provincial requirements.
Warning: Failure to observe the minimum waiting period or to maintain emergency supplies is considered a serious deviation from the standard. CSA Z1220-17 stresses that the safety of the patient is the primary responsibility of the immunization provider.
2.6 Documentation and Record Keeping
Each immunization encounter must generate a complete record that includes patient identification, vaccine product details (lot number, manufacturer, expiry date), site of injection, adverse events, and patient consent. Records must be retained for a period consistent with provincial legislation (often 10 years for adults, 10 years after age of majority for minors). Electronic health records integrated with vaccine registries are encouraged to support public health surveillance.
2.7 Infection Control and Occupational Safety
The standard mandates compliance with routine infection control practices: hand hygiene before and after each patient, use of gloves and other personal protective equipment (PPE) as indicated, proper sharps disposal, and surface disinfection between patients. Pharmacy professionals must be vaccinated themselves (e.g., hepatitis B, influenza) to protect both staff and patients.
3. Implementation Highlights for Pharmacy Practice
Implementing CSA Z1220-17 requires systematic changes to pharmacy operations. Successful adoption includes the following key steps:
- Policy Development: Draft written policies and procedures covering all elements of the standard, including staff roles, vaccination schedules, cold chain management, and emergency response.
- Workflow Integration: Design a dedicated vaccination area that ensures patient privacy, meets IPC requirements, and minimizes disruption to dispensing activities.
- Equipment Procurement: Install pharmacy-grade refrigerators with continuous temperature monitoring, maintain a well-stocked anaphylaxis kit, and have a backup power plan for temperature excursions.
- Staff Education: Train all personnel—including those supporting the service—on the standard’s requirements, data privacy, and their specific responsibilities.
- Collaboration with Public Health: Establish protocols for vaccine ordering, lot tracking, and AEFI reporting to align with provincial immunization registries.
Best Practice: Many Canadian pharmacies have achieved excellence by designating a “vaccine champion” who oversees compliance with CSA Z1220-17, conducts internal audits, and liaises with regulatory bodies. This role strengthens accountability and continuous improvement.
4. Compliance Notes and Auditing
Adherence to CSA Z1220-17 is typically evaluated by the provincial pharmacy regulatory authority (e.g., Ontario College of Pharmacists, Alberta College of Pharmacy) and may be integrated into routine pharmacy inspections. Compliance is measured through:
- Documentation Review: Inspectors examine a sample of patient records, consent forms, temperature logs, and training certificates.
- Observation: On-site visits may include observation of a vaccine preparation and administration session.
- Interviews: Pharmacy staff are asked about their training, emergency procedures, and knowledge of cold chain protocols.
- Self-Assessment Checklists: Many regulators provide a CSA Z1220-17 compliance checklist that pharmacies can use to perform internal audits.
Common non‑conformities include:
- Incomplete temperature records or lack of response to excursions
- Expired or missing staff certifications
- Inadequate post‑vaccination observation periods
- Improper sharps disposal or lack of PPE
Critical Compliance Risk: A pattern of non‑conformity—especially in cold chain management or adverse event reporting—can lead to suspension of the pharmacy’s authorization to provide immunization services. It is essential to maintain a rigorous quality management system and to act swiftly on any identified gaps.
Ongoing compliance requires periodic re‑evaluation of procedures, staff competency updates, and staying current with any amendments to the standard or related public health directives.
Q: Who is authorized to administer vaccines under CSA Z1220-17?
A: The standard applies to pharmacy professionals—pharmacists and, where permitted by provincial regulation, pharmacy technicians—who have completed an approved immunization training program and hold current certification. Additional restrictions may apply based on provincial scope-of-practice rules.
A: The standard applies to pharmacy professionals—pharmacists and, where permitted by provincial regulation, pharmacy technicians—who have completed an approved immunization training program and hold current certification. Additional restrictions may apply based on provincial scope-of-practice rules.
Q: What are the specific temperature requirements for vaccine storage?
A: Vaccines must be stored at +2°C to +8°C in a dedicated refrigerator. Continuous temperature monitoring with calibrated devices is required, and excursions outside this range must be documented and investigated. Ultra-cold vaccines (e.g., some COVID-19 products) have separate handling protocols that must also be integrated into the pharmacy’s procedures.
A: Vaccines must be stored at +2°C to +8°C in a dedicated refrigerator. Continuous temperature monitoring with calibrated devices is required, and excursions outside this range must be documented and investigated. Ultra-cold vaccines (e.g., some COVID-19 products) have separate handling protocols that must also be integrated into the pharmacy’s procedures.
Q: How often must immunization training be updated?
A: CSA Z1220-17 recommends recertification every two to three years. However, some provincial regulatory bodies may mandate more frequent updates. In all cases, pharmacy professionals must be able to demonstrate current knowledge of vaccine science, injection techniques, and emergency management.
A: CSA Z1220-17 recommends recertification every two to three years. However, some provincial regulatory bodies may mandate more frequent updates. In all cases, pharmacy professionals must be able to demonstrate current knowledge of vaccine science, injection techniques, and emergency management.
Q: Is adverse event reporting mandatory under this standard?
A: Yes. All adverse events following immunization (AEFI) must be documented and reported to the local public health authority in accordance with provincial regulations. The pharmacy must also have a process in place to monitor for patterns of AEFI that could indicate a product quality issue.
A: Yes. All adverse events following immunization (AEFI) must be documented and reported to the local public health authority in accordance with provincial regulations. The pharmacy must also have a process in place to monitor for patterns of AEFI that could indicate a product quality issue.
© 2026 Canadian Standards Association. This article provides an interpretive summary of CSA Z1220-17 and does not replace the official standard. For complete requirements, refer to the current edition of CSA Z1220-17 published by CSA Group.